Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00702910




Registration number
NCT00702910
Ethics application status
Date submitted
18/06/2008
Date registered
20/06/2008
Date last updated
10/08/2017

Titles & IDs
Public title
A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
Scientific title
A Randomised, Single-dose, Double-blind, Placebo-controlled, 5-way Crossover Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With and Without Magnesium Stearate in Asthmatic Patients
Secondary ID [1] 0 0
B2C111401
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - GW642444
Treatment: Drugs - Magnesium Stearate

Experimental: GW642444M/lactose - GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)

Experimental: GW642444M/MgSt - GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)

Placebo Comparator: Placebo - Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)


Treatment: Drugs: Placebo
comparator

Treatment: Drugs: GW642444
investigational drug or placebo

Treatment: Drugs: Magnesium Stearate
Magnesium Stearate
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change from baseline (pre-dose) FEV1 in trough (mean of the FEV1 values obtained 23 and 24 hours after dosing) FEV1
Timepoint [1] 0 0
on going
Secondary outcome [1] 0 0
Mean change from baseline (pre-dose) in FEV1 (i.e. derive separate responses for each FEV1 obtained over 24 hours after dosing).
Timepoint [1] 0 0
on going
Secondary outcome [2] 0 0
General safety and tolerability, including adverse events, laboratory safety tests (haematology, clinical chemistry and urinalysis), vital signs and, 12-lead ECG.
Timepoint [2] 0 0
on going
Secondary outcome [3] 0 0
Weighted mean and maximum value (0 - 4 h) QTc(B)
Timepoint [3] 0 0
on going
Secondary outcome [4] 0 0
Weighted mean and maximum value (0 - 4 h) QTc(F)
Timepoint [4] 0 0
on going
Secondary outcome [5] 0 0
Weighted mean and maximum value (0 - 4 h) supine heart rate
Timepoint [5] 0 0
on going
Secondary outcome [6] 0 0
Weighted mean and maximum value (0 - 4 h) supine systolic blood pressure
Timepoint [6] 0 0
on going
Secondary outcome [7] 0 0
Weighted mean and minimum value (0 - 4 h) supine diastolic blood pressure
Timepoint [7] 0 0
on going
Secondary outcome [8] 0 0
Weighted mean and maximum value glucose (0 - 4 h)
Timepoint [8] 0 0
on going
Secondary outcome [9] 0 0
Weighted mean and minimum value potassium (0 - 4 h)
Timepoint [9] 0 0
on going
Secondary outcome [10] 0 0
Single dose derived plasma pharmacokinetic parameters (AUC(0-t), Cmax, tmax) for GW642444 and GI179710 (triphenylacetate counterion)
Timepoint [10] 0 0
on going
Secondary outcome [11] 0 0
Estimate GW642444 concentration (Cmax) -systemic pharmacodynamic relationship for PD parameters, including heart rate, potassium & glucose levels
Timepoint [11] 0 0
on going

Eligibility
Key inclusion criteria
- Subjects with a documented history of persistent asthma, with the exclusion of other
significant pulmonary diseases (e.g. chronic bronchitis, emphysema, bronchiectasis,
cystic fibrosis or bronchopulmonary dysplasia).

- Male subjects or female subjects aged between 18 to 70 years.

- A female subject is eligible to participate if she is of:

- Non-childbearing potential defined as pre-menopausal females with a documented
tubal ligation or hysterectomy; or postmenopausal defined as 12 months of
spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (< 140
pmol/L) is confirmatory.

- Child-bearing potential and agrees to use one of the contraception methods listed
in Section 8.1 for an appropriate period of time (as determined by the product
label or investigator) prior to the start of dosing to sufficiently minimize the
risk of pregnancy at that point. Female subjects must agree to use contraception
until 2 days post last-dose.

- Subjects who are current non-smokers, who have not used any inhaled tobacco products
(snuff is permitted) in the 12 month period preceding the screening visit and who have
a pack history of = 10 pack years.

- Subjects with clinically stable, mild to moderate persistent asthma within the 4 weeks
preceding the screening visit and with a screening pre-bronchodilator FEV1 = 60 %
predicted as defined in the GINA guidelines [Global Initiative for Asthma (GINA),
2006] (having abstained from bronchodilators for the required period). Predicted
values are based on the ECCS 1993 normal ranges.

- Body weight = 50 kg and body mass index (BMI) within the range 19 - 29.9 kg/m2

- During the screening visit, subjects must demonstrate the presence of reversible
airway disease, defined as an increase in FEV1 of = 12.0% over baseline and an
absolute change of = 200 mL within 30 minutes following a single 400 mcg salbutamol
dose.

- ECG criteria as per protocol

- Subjects who are currently taking ICS at a total daily dose of 200 to 500 mcg of FP or
equivalent ICS.

- Subjects who are able and willing to give written informed consent to take part in the
study.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subjects who have a past or present disease, which as judged by the Investigator and
the Medical Monitor, which may affect the safety of the subject or outcome of this
study.

- A screening Holter ECG tracing that reveals clinically concerning arrhythmias.

- Subjects who have suffered an upper or lower respiratory tract infection within 4
weeks of the screening visit

- Subjects with a history of life-threatening asthma, defined as an asthma episode that
required intubation and/or was associated with either respiratory arrest or hypoxic
seizures.

- Asthma exacerbations requiring treatment with oral corticosteroids: any exacerbations
within 3 months of the screening visit or two or more exacerbations within 6 months of
the screening visit or admittance to hospital for an asthma exacerbation within 1 year
of the screening visit.

- Subjects classified as suffering from severe asthma as defined by the ATS guidelines

- Subjects who have taken high doses of an inhaled corticosteroid (> 500 mcg FP/day or
equivalent) within 8 weeks of the screening visit or oral steroids within 12 weeks of
the screening visit.

- Subjects who have changed their inhaled corticosteroid treatment within the last 6
weeks before screening or can be expected to do so during the study.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four NCE's within 12 months prior to the first dosing day

- Any adverse reaction including immediate or delayed hypersensitivity to any ß2 agonist
or sympathomimetic drug, or known or suspected sensitivity to the constituents of
GW642444 inhalation powder (e.g., lactose, milk protein, magnesium stearate).

- Subjects with a positive pre-study Hepatitis B surface antigen, positive Hepatitis C
antibody or HIV result (if tested as per site SOPs) within 3 months of the start of
the study.

- Neurological or psychiatric disease or history of drug or alcohol abuse which would
interfere with the subject's proper completion of the protocol requirements, including
compliance.

- Abuse of alcohol is defined as an average weekly intake of greater than 21 units or an
average daily intake of greater than 3 units (males) or defined as an average weekly
intake of greater than 14 units or an average daily intake of greater than 2 units
(females).

- 1 unit is equivalent to a half pint (220 mL) of beer or 1 measure (25 mL) of spirits
or 1 glass (125 mL) of wine.

- The subject has a positive pre-study urine drug test screen. A minimum list of drugs
that will be screened for include amphetamines, barbiturates, cocaine, opiates,
cannabinoids and benzodiazepines.

- The subject has a positive pre-study alcohol or smoking breath or urinary test.

- Where participation in the study would result in donation of blood in excess of 500 mL
within a 56 day period.

- Subjects with clinically relevant findings on laboratory safety tests.

- Subjects with laboratory values outside the reference range may be included if the
Investigator and medical monitor agree that these findings would not put the subject
at risk or interfere with the objectives of the study.

- Subjects with known hypersensitivity to salbutamol or any ingredient in this
preparation

- Subjects who have taken P-gp inhibitors and CYP 450 3A4 inhibitors (e.g. Ketoconazole)
within 6 weeks or theophyllines within 2 weeks of the screening visit.

- Inability to use the novel dry powder inhaler.

- Pregnant females as determined by positive hCG (serum or urine) test at screening or
prior to dosing.

- Lactating females.

- Unwillingness or inability to follow the procedures outlined in the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/04/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/10/2008
Sample size
Target
Accrual to date
Final
24
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Auchenflower
Recruitment hospital [2] 0 0
GSK Investigational Site - Clayton
Recruitment postcode(s) [1] 0 0
4066 - Auchenflower
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Wellington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will involve the use of a new medicine called GW642444 being developed for the
treatment of asthma and chronic obstructive pulmonary disease (COPD). The purpose of the
study is to see how safe and how well tolerated the study drug is when inhaled in two
different formulations as a fine powder by asthmatic patients. In addition, the study is
designed to examine the effect of the study drug on the lungs, how the study drug affects
parts of the body other than the lungs and to see how the body affects the study drug when it
is given in single doses.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00702910
Trial related presentations / publications
Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00702910